Abstract
Therapeutic management of lung cancer is mainly based on a dichotomic distinction between small cell (SCLC) and non-small cell lung cancer (NSCLC), tumour stage and patient performance status. However, crossing the recent data emerging from molecular studies of gene expression profiling, from the new 2004-WHO histopathological classification of lung tumours as well as from clinical trials with newl targeted therapies against EGFR (gefitinib/ erlotinib/cetuximab), it seems that a better definition of tumour histotype in NSCLC might somehow be helpful in predicting clinical response and patient outcome. In addition, lung tumours histotype may deeply influence the tumour stage when assessing parameters (i.e., pulmonary atelectasis, pleural invasion, tumour dimension) defining the current lung tumours staging system. Thus, in this review we analyze the possible future role of histotype as an important influencing factor in the clinical management of patients with NSCLC.
Keywords: Lung, histotype, cancer, WHO, classification, EGFR
Current Respiratory Medicine Reviews
Title: Histotype in Non-Small Cell Lung Cancer Therapy and Staging: The Emerging Role of an Old and Underrated Factor
Volume: 3 Issue: 1
Author(s): Giulio Rossi, Alessandro Marchioni, Giuliana Sartori, Lucia Longo, Silvia Piccinini and Alberto Cavazza
Affiliation:
Keywords: Lung, histotype, cancer, WHO, classification, EGFR
Abstract: Therapeutic management of lung cancer is mainly based on a dichotomic distinction between small cell (SCLC) and non-small cell lung cancer (NSCLC), tumour stage and patient performance status. However, crossing the recent data emerging from molecular studies of gene expression profiling, from the new 2004-WHO histopathological classification of lung tumours as well as from clinical trials with newl targeted therapies against EGFR (gefitinib/ erlotinib/cetuximab), it seems that a better definition of tumour histotype in NSCLC might somehow be helpful in predicting clinical response and patient outcome. In addition, lung tumours histotype may deeply influence the tumour stage when assessing parameters (i.e., pulmonary atelectasis, pleural invasion, tumour dimension) defining the current lung tumours staging system. Thus, in this review we analyze the possible future role of histotype as an important influencing factor in the clinical management of patients with NSCLC.
Export Options
About this article
Cite this article as:
Rossi Giulio, Marchioni Alessandro, Sartori Giuliana, Longo Lucia, Piccinini Silvia and Cavazza Alberto, Histotype in Non-Small Cell Lung Cancer Therapy and Staging: The Emerging Role of an Old and Underrated Factor, Current Respiratory Medicine Reviews 2007; 3 (1) . https://dx.doi.org/10.2174/157339807779941820
DOI https://dx.doi.org/10.2174/157339807779941820 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanostructural Hybrid Sensitizers for Photodynamic Therapy
Current Pharmaceutical Design Aldose Reductase Inhibitors and Nanodelivery of Diabetic Therapeutics
Mini-Reviews in Medicinal Chemistry Recent Advances in Application of Poly-Epsilon-Caprolactone and its Derivative Copolymers for Controlled Release of Anti-Tumor Drugs
Current Cancer Drug Targets Brain Tumor Causes, Symptoms, Diagnosis and Radiotherapy Treatment
Current Medical Imaging High-Throughput Functional Genomic Methods to Analyze the Effects of Dietary Lipids
Current Pharmaceutical Biotechnology Review of Advanced Airway Cryosurgical Techniques
Current Respiratory Medicine Reviews Genomic Profiles and Current Therapeutic Agents in Neuroendocrine Neoplasms
Current Drug Targets Advances in Hyaluronic Acid-Based Drug Delivery Systems
Current Drug Targets The Common Mycobacterial Antigens and their Importance in the Treatment of Disease
Current Pharmaceutical Design The Role of Pemetrexed Combined with Targeted Agents for Non-Small Cell Lung Cancer
Current Drug Targets Compounds Derived from Epigallocatechin-3-Gallate (EGCG) as a Novel Approach to the Prevention of Viral Infections
Inflammation & Allergy - Drug Targets (Discontinued) siRNA Delivery by Stimuli-Sensitive Nanocarriers
Current Pharmaceutical Design Synthetic Approach for Substituted 3-Amino-1,2,4-Triazines and their Chemical Reactivity and Biological Properties
Mini-Reviews in Organic Chemistry The PI3K/Akt Pathway as a Target in the Treatment of Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry Antisense Technology: A Selective Tool for Gene Expression Regulation and Gene Targeting
Current Pharmaceutical Biotechnology Perspective on Nanoparticle Technology for Biomedical Use
Current Pharmaceutical Design The Current View on the Helicase Activity of RNA Helicase A and Its Role in Gene Expression
Current Protein & Peptide Science Recent Development of Drug Delivery Systems for the Treatment of Asthma and Related Disorders
Recent Patents on Inflammation & Allergy Drug Discovery CT Image Reconstruction Using NLMfuzzyCD Regularization Method
Current Medical Imaging Triazene Compounds in the Treatment of Acute Myeloid Leukemia: A Short Review and a Case Report
Current Medicinal Chemistry